Highlights

• Organic revenue growth was 7%. Revenue in DKK was up by 8% to DKK 9,537m.
• Organic growth rates by business area: Ostomy Care 7%, Urology & Continence Care 9%. Sales in Wound & Skin Care were unchanged from last year. 
• Gross profit was up by 15% to DKK 5,844m. Gross margin of 61%, up from 58% last year.
• EBIT was up by 43% to DKK 1,995m. The EBIT margin was 21% against 16% last year. At constant exchange rates, the EBIT margin was 20%. Consequently, the current long-term financial targets were met.
• The free cash flow improved by DKK 48m relative to last year to DKK 1,476m.  
• ROIC after tax was 23%, compared with 15% last year.
• The Board of Directors recommends that the Annual General Meeting to be held on 1 December 2010 approve a dividend of DKK 10.00 per share against DKK 7.00 last year, equal to a pay-out ratio of 34%, which is unchanged from last year.
• Coloplast's new long-term financial ambition is to continue to outgrow the market and achieve EBIT margins that are in line with the best performing med-tech companies.
• Financial guidance for 2010/11
  
• We expect organic revenue growth of 6-8% both at constant exchange rates and in DKK.
• We expect an EBIT margin of 23-25%, both at constant exchange rates and in DKK.
  
  Capital expenditure is expected to be DKK 300–400m.
• The effective tax rate is expected to be around 26%.